Zobrazeno 1 - 10
of 503
pro vyhledávání: '"Ghassan K Abou-Alfa"'
Autor:
Amaia Lujambio, Thomas Yau, Lipika Goyal, Andrew X Zhu, Ignacio Melero, Tim F Greten, Ann-Lii Cheng, Bruno Sangro, David J Pinato, Peter R Galle, Ghassan K Abou-Alfa, Austin G Duffy, Anthony B. El-Khoueiry, Richard S Finn, Aiwu Ruth He, Ahmed O Kaseb, Robin Kate Kelley, Riccardo Lencioni, Donna Mabry Hrones, Roberto I Troisi, Andrea Wilson Woods
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC ha
Externí odkaz:
https://doaj.org/article/c395a80c692945e793e9d243958829ae
Autor:
Ghassan K. Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, Sarina A. Piha-Paul, Joseph S. Light, Scott Sherrin, Amin Yaqubie, Alison Clemens O’Neill, James J. Harding, Raed Al-Rajabi, Crystal S. Denlinger, Pablo Cano, Albert S. Cornelius, Eileen M. O'Reilly, Daniel DiPrimeo, Lisa D. Eli, John D. Gordan, David B. Solit
Publikováno v:
Liver Cancer, Pp 1-10 (2024)
Introduction: Fibrolamellar carcinoma (FLC) displays upregulation of several oncogenes, including HER2, and multiple immune-suppressive mechanisms. We investigated the efficacy and safety of the pan-HER tyrosine kinase inhibitor neratinib as monother
Externí odkaz:
https://doaj.org/article/060277f2d7054affa161c9c60698ca95
Autor:
Sebastián Mondaca, Henry Walch, Santiago Sepúlveda, Nikolaus Schultz, Gonzalo Muñoz, Amin Yaqubie, Patricia Macanas, Claudia Pareja, Patricia Garcia, Walid Chatila, Bruno Nervi, Bob Li, James J. Harding, Paola Viviani, Juan Carlos Roa, Ghassan K. Abou-Alfa
Publikováno v:
JCO Global Oncology, Iss 10 (2024)
PURPOSEGallbladder cancer (GBC) is a biliary tract malignancy characterized by its high lethality. Although the incidence of GBC is low in most countries, specific areas such as Chile display a high incidence. Our collaborative study sought to compar
Externí odkaz:
https://doaj.org/article/3e177846e0ea4a48b47dc3c144723c3a
Publikováno v:
American Heart Journal Plus, Vol 43, Iss , Pp 100406- (2024)
Externí odkaz:
https://doaj.org/article/e5154e7dbf6b44dba49bd2675fa1b0d2
Autor:
Sara Velayati, Ahmed Elsakka, Ken Zhao, Joseph P. Erinjeri, Brett Marinelli, Mohamed Soliman, Olivier Chevallier, Etay Ziv, Lynn A. Brody, Constantinos T. Sofocleous, Stephen B. Solomon, James J. Harding, Ghassan K. Abou-Alfa, Michael I. D’Angelica, Alice C. Wei, Peter T. Kingham, William R. Jarnagin, Hooman Yarmohammadi
Publikováno v:
Current Oncology, Vol 30, Iss 10, Pp 9181-9191 (2023)
The safety and efficacy of hepatic artery embolization (HAE) in treating intrahepatic cholangiocarcinoma (IHC) was evaluated. Initial treatment response, local tumor progression-free survival (L-PFS), and overall survival (OS) were evaluated in 34 IH
Externí odkaz:
https://doaj.org/article/7cbeab7a43d54e31aadc95f47c6af60a
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 13978-13990 (2023)
Abstract Hepatocellular carcinoma (HCC) is a major cause of death among patients with liver cirrhosis. The rise of immuno‐oncology has revolutionized treatment for advanced HCC. However, most pivotal randomized controlled trials have excluded patie
Externí odkaz:
https://doaj.org/article/747696b1fb5b4f988dbf26409b98fa8a
Autor:
Fernanda Capareli, Frederico Costa, Jack A. Tuszynski, Micelange C. Sousa, Yone de C. Setogute, Pablo D. Lima, Luciana Carvalho, Elizabeth Santos, Brenda P. Gumz, Jorge Sabbaga, Tiago B. deCastria, Denis L. Jardim, Daniela Freitas, Natally Horvat, Regis O. F. Bezerra, Leonardo Testagrossa, Tiago Costa, Tatiana Zanesco, Antonio F. Iemma, Ghassan K. Abou‐Alfa
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12402-12412 (2023)
Abstract Background Patients with advanced hepatocellular carcinoma (HCC) and poor liver function lack effective systemic therapies. Low‐energy electromagnetic fields (EMFs) can influence cell biological processes via non‐thermal effects and may
Externí odkaz:
https://doaj.org/article/e607313da1734bf38413f03a8853d977
Autor:
Travis Zack, Kurt P. Losert, Samantha M. Maisel, Jennifer Wild, Amin Yaqubie, Michael Herman, Jennifer J. Knox, Robert J. Mayer, Alan P. Venook, Atul Butte, Allison F. O’Neill, Ghassan K. Abou-Alfa, John D. Gordan
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-6 (2023)
Abstract The incidence and biochemical consequences of rare tumor subtypes are often hard to study. Fibrolamellar liver cancer (FLC) is a rare malignancy affecting adolescents and young adults. To better characterize the incidence and biochemical con
Externí odkaz:
https://doaj.org/article/a6be12a913714c2aaed7398302e34be1
Autor:
James J. Harding, Sarina A. Piha-Paul, Ronak H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
In biliary tract cancer HER2 alterations correlate with poor prognosis. Here, the authors present the results of a phase II clinical trial reporting the efficacy and safety of the tyrosine kinase inhibitor neratinib in patients with HER2-mutation pos
Externí odkaz:
https://doaj.org/article/6b0c6dc798b14d37bd9664bd41aec7e1
Autor:
Ghassan K. Abou-Alfa, Mary Afihene, Marinela Capanu, Yuelin Li, Joanne F. Chou, Akwi Asombang, Olusegun Isaac Alatise, Adda Bounedjar, Lina Cunha, Hailemichael Desalegn Mekonnen, Papa Saloum Diop, Reda Elwakil, Mahamat Moussa Ali, Ntokozo Ndlovu, Jerry Ndumbalo, Precious Takondwa Makondi, Christian Tzeuton, Tiago Biachi de Castria, Adwoa Afrakoma Agyei-Nkansah, Fiyinfolu Balogun, Alain Bougouma, Blaise Irénée Atipo Ibara, Eduard Jonas, Stephen Kimani, Peter Kingham, Reshad Kurrimbukus, Nazik Hammad, Mona Fouad, Noha El Baghdady, Eloumou Bagnaka Servais Albert Fiacre, Vikash Sewram, C. Wendy Spearman, Ju Dong Yang, Lewis R. Roberts, Ashraf O. Abdelaziz
Publikováno v:
JCO Global Oncology, Vol , Iss 9 (2023)
PURPOSEHepatocellular carcinoma (HCC), the fourth most common cancer in Africa, has a dismal overall survival of only 3 months like in sub-Saharan Africa. This is affected by the low gross domestic product and human development index, absence of cohe
Externí odkaz:
https://doaj.org/article/bb11425805f648a1a198b8b80e8b96bf